Skip to content

Enhancing Inpatient Psychotherapeutic Treatment With Online Self-help : Acceptance and Efficacy

Enhancing Inpatient Psychotherapeutic Treatment With Online Self Help in a Randomised Controlled Trial: Acceptance and Efficacy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02196896
Enrollment
229
Registered
2014-07-22
Start date
2014-06-30
Completion date
2016-11-30
Last updated
2017-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

The purpose of this study is to determine the acceptance and efficacy of the online self-help program deprexis® for depressed patients in reducing the clinical symptoms of their depression. The patients of the experimental group use deprexis® for 90 days, the patients of the placebo group receive weekly online information about depression for 90 days as well. Both groups receive their treatment in addition to their regular inpatient psychosomatic treatment and as an aftercare intervention.The investigators hypothesize that the online self-help group achieves a greater reduction of depression compared to the control group.

Interventions

OTHERdeprexis®

Online self-help program in addition to inpatient psychosomatic treatment for 90 days.

OTHERInformation

The patients receive online information about depression once a week for 90 days.

Sponsors

Rhön-Klinikum AG
CollaboratorUNKNOWN
Johannes Gutenberg University Mainz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Inpatient treatment * Private internet access * Informed consent * Age between 18 and 65 years * Knowledge of the German language * Score in the BDI-II \> 13 and clinical diagnosis of a depression (ICD-10: F32.x, F33.x, F34.1, F43.2) verified by the inpatient therapist

Exclusion criteria

* Psychosis * Current alcohol or drug dependency * Borderline, antisocial, schizoid or schizotypal personality disorder * Anorexia nervosa * Life time diagnosis of a schizophrenia, schizoaffective , bipolar oder organic psychic disorder

Design outcomes

Primary

MeasureTime frame
Reduction of depression measured with the Beck's Depression Inventory (BDI-II)Three months after randomization

Secondary

MeasureTime frameDescription
Reduction of depression measured with the Beck's Depression Inventory (BDI-II)Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Reduction of anxiety measured with the Generalized Anxiety Disorder Scale (GAD-7)Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Reduction of dysfunctional depression related cognitions measured with the Dysfunctional Attitude Scale (DAS)Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Improved self-esteem measured with the Rosenberg Self-Esteem Scale (RSE)Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Improved quality of life measured with the European Health Interview Survey Quality of Life-8 (EUROHIS-QOL 8)Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Improved working ability measured with the short form of the Work Ability Index (WAI)Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Acceptance and utilization of deprexis® measured with a self devised questionnaireEnd of inpatient treatment (average 6 weeks), three months after randomization
Acceptance and utilization of the information used in the placebo condition measured with a self devised questionnaireEnd of inpatient treatment (average 6 weeks), three months after randomization
Reduction of depression measured with the depression scale of the Patient Health Questionnaire (PHQ-9)Randomization, end of inpatient treatment (average 6 weeks), six months after randomization
Degree of structural deficits measured with the short form of the OPD-Structure Questionnaire (OPD-SFK)RandomizationAssumption that structural deficits, as assessed with the OPD-SFK questionnaire at the beginning of treatment have a moderating effect on the reduction in the primary outcome measure.
Therapeutic alliance between participant and inpatient psychotherapist measured with the Helping Alliance Questionnaire (HAQ).Randomization, end of inpatient treatment (average 6 weeks)
Course of mood, depressiveness and utilization of unitsDuring inpatient treatment (average 6 weeks)
Utilization of other treatments after the end of inpatient treatmentSix months after randomization
Satisfaction with inpatient treatmentEnd of inpatient treatment (average 6 weeks)
Willingness to payThree months after randomization
Remission from depressionEnd of inpatient treatment (average 6 weeks), three months after randomization, six months after randomizationBDI score below the cutoff of 13 and a reliable change regarding Reliable Change Index (RCI)
Degree of childhood traumas measured with the Childhood Trauma Questionnaire (CTQ)RandomizationAssumption that childhood traumas, assessed at the beginning of treatment, have a moderating effect on the reduction in the primary outcome measure.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026